Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Estrella Immunopharma ( (ESLA) ) has provided an announcement.
On September 22, 2025, Estrella Immunopharma appointed Jia Dengyao to its Board of Directors. The company also entered into an indemnification agreement with Mr. Jia, ensuring coverage of certain expenses related to his role as a director.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc. operates in the biotechnology industry, focusing on developing immunotherapy solutions.
Average Trading Volume: 23,024
Technical Sentiment Signal: Buy
Current Market Cap: $43.97M
For an in-depth examination of ESLA stock, go to TipRanks’ Overview page.